A pentapeptide with sleep-promoting activity and its application
The pentapeptide TPTLN isolated through casein hydrolysis solves the problem of insufficient research on food-borne small molecule peptides in improving sleep, and achieves the effect of significantly shortening the latency period of sleep and prolonging sleep time. It is safe and has no side effects. It is suitable for food and Health care products.
Patent Information
- Application Number
- CN202410158029.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-02-04
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-02-04
AI Technical Summary
In the prior art, there is insufficient research on foodborne small molecule peptides in improving sleep, especially whether the casein hydrolysate contains other peptides with sleep-enhancing activity has not been fully developed.
A novel pentapeptide TPTLN (Thr-Pro-Thr-Leu-Asn) was isolated and identified by casein hydrolysis, which can be obtained by chemical solid phase synthesis or from casein hydrolysate and isolate with other aids Sleep ingredients are mixed and prepared into microcapsules to improve bioavailability and delay shelf life.
五肽TPTLN能够显著缩短小鼠的入睡潜伏期并延长睡眠时间,安全无毒副作用,能够与GABAA受体结合,激活受体以起到助睡眠的功效。
Smart Images

Figure CN117964692B_ABST
Abstract
Description
Technical field:
[0001] The invention belongs to the field of food health, and in particular relates to a pentapeptide that can be applied to people suffering from sleep deficiency or sleep disorders (difficulty falling asleep or poor sleep quality). Background technology:
[0002] Sleep is a physiological activity that plays an important role in human health. About one-third of a person's life is spent in sleep. Sleep can help the brain's nervous system store and restore energy, strengthen brain connections, and help improve people's learning and memory abilities. Lack of sleep will not only make people feel weak, slow to react, memory decline, and reduced immunity, but also cause endocrine disorders in the body. People who lack sleep are more likely to be obese, and at the same time have a higher risk of chronic diseases such as hypertension, diabetes, and coronary heart disease. According to the World Health Organization, 27% of people worldwide suffer from sleep disorders. The "New Era of Healthy Sleep: 2023 China Healthy Sleep White Paper" of the China Sleep Research Society shows that nearly 90% of the respondents are concerned about sleep health, and up to 80% of the respondents have sleep problems such as reduced sleep time, difficulty falling asleep, and insomnia. With the increasing number of people with sleep disorders and the trend of younger age, consumers' demand for sleep-aiding products has also increased sharply, among which melatonin and γ-aminobutyric acid are the most popular.
[0003] Although sedatives and hypnotic drugs represented by benzodiazepines on the market are effective, long-term use will bring many side effects, such as drug resistance and addiction. Therefore, it is necessary to find and develop safer food-derived bioactive substances as a natural therapy. Food-derived active peptides can not only provide rich nutrients for humans, but also have many biological functions, such as lowering blood pressure, anti-inflammatory, anti-oxidation, anti-type 2 diabetes and anti-cancer.
[0004] Cow's milk itself is regarded as a healthy food that can calm the nerves and promote sleep. Casein accounts for more than 80% of the total protein in cow's milk. Many studies have shown that bioactive peptides derived from cow's milk casein have opioid activity and can calm the nerves and promote sleep.
[0005] Chinese patent CN 112409470 A "A casein peptide with sleep-improving effect, preparation method and application thereof" discloses casein octapeptide KLPPVGPY (Lys-Leu-Pro-Pro-Val-Gly-Pro-Tyr) and decapeptide APIASLLPPY (Ala-Pro-Ile-Ala-Ser-Leu-Leu-Pro-Pro-Tyr) with sleep-improving effect.
[0006] U.S. Patent US005846939A "USE OF A DECAPEPTIDE WITH BENZODIAZEPINE-TYPEACTIVITY FOR PREPARING MEDICNES AND FOOD SUPPLEMENTS" discloses an αS1-casein-derived α-CZP homologous sequence anti-anxiety decapeptide YLGYLEQLLR (Tyr-Leu-Gly-Tyr -Leu-Glu-Gln-Leu-Leu-Arg) with Tyr at the N-terminus and a molecular weight of 1267 Da.
[0007] Chinese patent CN 200980120762.2 discloses an anti-anxiety composition comprising αS1-casein peptides, and proposes a biosynthetic or chemical synthesis method to prepare two peptides: the pentapeptide YLGYL (Tyr-Leu-Gly-Tyr-Leu) with a molecular weight of 627 Da and the hexapeptide YLGYLE (Tyr-Leu-Gly-Tyr-Leu-Glu) having antianxiety activity.
[0008] Chinese patent CN 114106096 A "A hexapeptide with sleep-improving activity and its application" discloses a hexapeptide with sleep-improving activity and its application. The primary structure amino acid sequence of the hexapeptide is YPVEPF (Tyr-Pro-Val-Glu-Pro-Phe) and the molecular weight is 750.85 Da.
[0009] Chinese patent CN 113754751 A "A novel sleep-promoting milk-derived active peptide CCL-2S and its preparation method and application" discloses a sleep-promoting milk-derived active octapeptide FALPQYLK (Phe-Ala-Leu-Pro-Gln-Tyr-Leu-Lys) with a molecular weight of 979.17 Da.
[0010] Chinese patent CN 111632130 A "Application of milk-derived active peptide CCL-3S in the preparation of sleep-promoting products" discloses a sleep-promoting milk-derived active 15-peptide with an amino acid sequence of HQGLPQEVLNENLLR (His-Gln-Gly-Leu-Pro-Gln-Glu-Val-Leu-Asn-Glu-Asn-Leu-Leu-Arg) and a molecular weight of 1759.998 Da.
[0011] Chinese patent CN 113735957 A "A novel sleep-promoting milk-derived active peptide CCL-4S and its preparation method and application" discloses a novel sleep-promoting milk-derived active undecapeptide with an amino acid sequence of VAPFPEVFGKE (Val-Ala-Pro-Phe-Pro-Glu-Val-Phe-Gly-Lys-Glu) and a molecular weight of 1219.38 Da.
[0012] In the prior art, casein trypsin hydrolysate containing the anti-anxiety decapeptide YLGYLEQLLR (α-CZP) has been shown to significantly prolong the sleep time induced by sodium pentobarbital in rats. In the prior art, casein hydrolysate containing the hexapeptide YPVEPF has also been shown to significantly prolong the sleep time induced by sodium pentobarbital in mice. However, it is still unknown whether the casein hydrolysate contains other peptides with sleep-improving activity. In addition, published Chinese patents disclose that octapeptides, decapeptides, 15-peptides, etc. derived from bovine milk casein have the effect of improving sleep, but research on food-derived small molecule peptides with sleep-improving activity is still insufficient, and new active peptides with sleep-promoting effects need to be further developed. Summary of the invention:
[0013] In order to develop new food-borne bioactive functional peptides with sleep-promoting activity and provide a reference for functional products with casein hydrolysate as a sleep-promoting active ingredient, the present invention uses casein as raw material, hydrolyzes it, and separates and identifies a new peptide with sleep-promoting activity.
[0014] One of the technical solutions provided by the present invention is a pentapeptide, the amino acid sequence of the pentapeptide is TPTLN (Thr-Pro-Thr-Leu-Asn), the molecular weight is 544 Da, and the active peptide segment is derived from αS2 casein (f120-124).
[0015] Furthermore, the pentapeptide TPTLN can be prepared by chemical solid phase synthesis;
[0016] Furthermore, the pentapeptide TPTLN can also be separated and obtained from casein hydrolysate; the casein is bovine casein or other mammalian casein;
[0017] Furthermore, the method for obtaining pentapeptide TPTLN from casein hydrolysate is as follows:
[0018] Take 250-300 kg of casein and add it to 1000 kg of water, stir and soak it at room temperature for 30-60 min, stir and heat it to 40-45°C, adjust the pH of the liquid to 7.0±0.2 with a sodium hydroxide aqueous solution, and stir and fully dissolve it at 40-45°C for 30-90 min; after there are no obvious white particles in the liquid, add 0.1-10.0‰ of composite protease ("‰" is calculated by the mass of casein substrate), after enzymolysis for 30-60 min, adjust the pH of the liquid to 7.0±0.2 with a sodium hydroxide aqueous solution, continue enzymolysis for 2-2.5 hours, and then add 0.1-10.0‰ of papain ("‰" is calculated by the mass of casein substrate), and continue enzymolysis for 1-2 hours; after the enzymolysis is completed, centrifuge the enzymatic hydrolyzate, take the supernatant, concentrate, sterilize and spray-dry, and obtain the final casein hydrolyzate. The casein hydrolysate was subjected to Q Exactive™ Hybrid Quadrupole-Orbitrap™ LC-MS / MS analysis, and the raw files of the original mass spectrometry results were subjected to De novo analysis to obtain multiple peptides including TPTLN.
[0019] Furthermore, the composite protease is composed of neutral protease, papain and trypsin in a mass ratio of 1-5:1-9:1-3.
[0020] The second technical solution provided by the present invention is the application of the pentapeptide TPTLN, especially in improving sleep, more particularly in the preparation of medicines for preventing, improving or treating sleep disorders, or in the preparation of foods for improving sleep disorders, or in the preparation of health products for improving sleep disorders;
[0021] The sleep disorders include, but are not limited to: reduced sleep time, difficulty falling asleep, insomnia, poor sleep quality, etc.;
[0022] Furthermore, the pentapeptide TPTLN can be used alone in the preparation of the food, health care product or medicine; or it can be used in combination with other components having sleep-aiding activity;
[0023] The components with sleep-promoting activity include, but are not limited to, Chinese medicinal materials that are both medicinal and edible (such as spiny jujube seeds, longan, lily, jujube, gardenia, tuckahoe, lotus seeds, honey, licorice, nutmeg, bergamot and mame, etc.), tryptophan, melatonin, γ-aminobutyric acid (GABA), etc. and other protein peptides;
[0024] Furthermore, the pentapeptide TPTLN is prepared into beverages, oral liquids, capsules, dripping pills, sustained-release preparations, injections, microcapsule powders, tablets, granules or emulsion tablets, etc.;
[0025] Preferably, the pentapeptide TPTLN is prepared into microcapsules to improve the gastrointestinal digestion stability, bioavailability and shelf life of the pentapeptide, so that it can be better applied in the food industry and health care fields.
[0026] The third technical solution provided in this scheme is a composition comprising pentapeptide TPTLN, wherein the composition has TPTLN as the only active ingredient and may also contain other components having sleep-aiding activity and / or auxiliary materials.
[0027] Beneficial effects:
[0028] The pentapeptide with sleep-promoting activity provided by the present invention can be chemically synthesized or directed prepared from bovine casein enzymatic hydrolysates or other mammalian casein enzymatic hydrolysates, can be used alone in health products and medicines for improving sleep, can be used in combination with other components with sleep-promoting activity, and can also be prepared into microcapsules to improve the gastrointestinal digestion stability, bioavailability and shelf life of the pentapeptide, so that it can be better used in the food industry and health care fields.
[0029] The peptide TPTLN of the present invention is derived from the food-derived casein hydrolysate prepared by the applicant, which is safe, nutritious, and has no toxic side effects. TPTLN can be combined with GABA A Receptor binding, binding sites are: SER205, ASN60, TYR210, GLU138, THR207, LYS156, ASN103 and SER195, activate GABA A TPTLN at a dose of 5 mg / kg can significantly shorten the latency to fall asleep and prolong the sleep time of mice. Description of the drawings:
[0030] Figure 1 Total ion profile of casein hydrolysate.
[0031] Figure 2 MS / MS spectrum of TPTLN.
[0032] Figure 3 Sequence of TPTLN.
[0033] Figure 4 GABA A Schematic diagram of molecular docking of receptor 6HUO and pentapeptide TPTLN.
[0034] Figure 5 Effects of TPTLN on sleep latency (A) and sleep duration (B) in mice.
[0035] Figure 6 Effects of TPTLN on sleep-related neurotransmitters in mouse serum;
[0036] Among them (A) 5-HT, (B) GABA, (C) NE, (D) Glu, (E) 5-HIAA, (F) β-EP, (G) Cortisol, (H) GABA / Glu;
[0037] Note: “*”: compared with the control group, p<0.05; “**”: compared with the control group, p<0.01.
[0038] Figure 7 Effects of TPTLN on sleep-related neurotransmitters in mouse brain tissue;
[0039] Among them (A) 5-HT, (B) GABA, (C) NE, (D) Glu, (E) β-EP, (F) Cortisol, (G) GABA / Glu;
[0040] Note: “*”: compared with the control group, p<0.05; “**”: compared with the control group, p<0.01. Specific implementation method:
[0041] The present invention is described below by specific embodiments. Unless otherwise specified, the technical means used in the present invention are methods known to those skilled in the art. In addition, the embodiments should be understood as illustrative rather than limiting the scope of the present invention, and the essence and scope of the present invention are limited only by the claims. For those skilled in the art, various changes or modifications to the material composition and dosage in these embodiments, without departing from the essence and scope of the present invention, also belong to the protection scope of the present invention.
[0042] The present invention is further explained below through specific implementation modes.
[0043] Example 1 Analysis and Identification of TPTLN
[0044] (1) Casein pretreatment
[0045] Take 250 kg of casein (cow milk casein) and add it to 1000 kg of water. Stir and soak it at room temperature for 60 min. After stirring and heating to 40-45°C, adjust the pH of the liquid to 7.0±0.2 with 7.5% sodium hydroxide aqueous solution, and stir and fully dissolve it at 40-45°C for 60 min.
[0046] (2) Casein enzymatic hydrolysis
[0047] After no obvious white particles are present in the feed liquid, 0.4‰ (w / w, "‰" is calculated based on the mass of the casein substrate) of a composite protease is added, including a neutral protease, papain, and trypsin in a mass ratio of 1:3:1 (the neutral protease is derived from Aspergillus oryzae fermentation, with a preservation number of CGMCC No.7586, and the specific preparation method refers to Example 1 of Chinese invention patent ZL201510176420.X), after half an hour of enzymolysis, the pH of the feed liquid is adjusted to 7.0±0.2 with a 7.5% sodium hydroxide aqueous solution, and the enzymolysis is continued for 2.5 hours, and then 0.5‰ (w / w, "‰" is calculated based on the mass of the casein substrate) of papain is added, and the enzymolysis is continued for 1.5 hours; after the enzymolysis is completed, the enzymatic hydrolyzate is separated by a butterfly separator, and the supernatant is taken, concentrated and sterilized, and then spray-dried to obtain the final casein hydrolyzate.
[0048] (3) Peptide analysis
[0049] The hydrolysate was subjected to LC-MS / MS peptide spectrum analysis to obtain the peptides contained in the casein hydrolysate, and the peptides were sorted and classified. Finally, the bioinformatics method was used to further perform molecular docking on the initially screened peptides, and the final theoretical effective peptides were determined based on the scores. The specific analysis process is as follows:
[0050] ① Pretreatment of peptide samples:
[0051] Use 100 μL 50 mM NH 4 HCO 3 The casein hydrolysate sample obtained by spray drying was re-dissolved, and DTT solution was added to make the final concentration of 10 mmol / L, and reduced in a 56°C water bath for 1 h. Then IAA solution was added to make the final concentration of 50 mmol / L, and the reaction was protected from light for 40 min. Finally, a self-filled desalting column was used for desalting, and the solvent was evaporated in a vacuum centrifugal concentrator at 45°C.
[0052] ② Analysis of casein hydrolysate samples by LC-MS / MS
[0053] Capillary liquid chromatography conditions:
[0054] 1) Analytical column: 150 μm id × 150 mm, packed with Acclaim PepMap RPLC C18, 1.9 μm, 100Å;
[0055] 2) Mobile phase A: 0.1% formic acid; Mobile phase B: 0.1% formic acid, 80% ACN;
[0056] 3) Flow rate: 600 mL / min;
[0057] 4) Analysis time for each component: 66 min. Mobile phase method: 0 min, 4%B; 2 min, 8%B; 45 min, 28%B; 55 min, 40%B; 56 min, 95%B; 66 min, 95%B.
[0058] Mass spectrometry parameters:
[0059] 1) Primary mass spectrometry parameters: Resolution: 70,000; AGCtarget: 3e6; MaximumIT: 100 ms;
[0060] Scanrange: 300 to 1800 m / z.
[0061] 2) Secondary mass spectrometry parameters: Resolution: 17,500; AGCtarget: 1e5; MaximumIT: 50 ms; TopN: 20; NCE / steppedNCE: 28.
[0062] The raw file generated by LC-MS / MS data acquisition of casein hydrolysate sample is opened with Xcalibur, and you can see Figure 1 Total ion current chromatogram shown.
[0063] ③Molecular docking
[0064] The mass spectrometry raw files were analyzed for peptide sequences using the De novo method, and the peptides identified by mass spectrometry were combined with GABA using Schrodinger software. A The receptor 6HUO was docked in batches, and the docking module selected the ligant docking module high-throughput screening option. A The identified peptides were classified and screened based on the docking site of the receptor protein 6HUO, the number of hydrogen bonds between the ligand and the receptor, the number of repetitions of the binding site with benzodiazepines (BZDs), and the protein source. Finally, two pentapeptides (TPTLN, VPYPQ) and two hexapeptides (YVPLGT, YAKPAA) were determined for in vitro chemical synthesis and in vivo animal experimental verification (as shown in Table 1).
[0065] Among them, the secondary mass spectrum of the pentapeptide TPTLN is as follows Figure 2 The peptide sequence is shown in Figure 3As shown in the figure, the fragment ions of peptides include: N-terminal fragment ions (a, b, c types) and C-terminal fragment ions (x, y, z types). The side chains of a, y, and z type ions break to form d, v, and w type ions respectively. In addition, there are internal ions formed by the breakage of both ends. The b and y series ions are the most common. The primary structure of the peptide can be analyzed and inferred based on the b or y series fragment ions of the peptide. Figure 2 m / z 545.29181 is the [M+H] of pentapeptide + ion signal, which is consistent with the molecular weight of the pentapeptide of 544. The pentapeptide was further analyzed by secondary mass spectrometry using in-source collision-induced dissociation technology ( Figure 3 ), the primary structure of the pentapeptide was determined to be Thr-Pro-Thr-Leu-Asn.
[0066] The docking results of the ligant docking module (accuracy option selected) of the pentapeptide TPTLN and the animal experiments are shown in Examples 2 and 3.
[0067] Table 1: Molecular docking results of four casein hydrolyzed peptides using Schrodinger
[0068]
[0069] Note: The lower the docking score, the better the binding between the small molecule peptide ligand and the protein receptor.
[0070] Example 2: GABA A Molecular docking of receptor 6HUO and pentapeptide TPTLN
[0071] The pentapeptide TPTLN in casein hydrolysate has the potential functional activity of promoting sleep. In Example 1, the peptides obtained by mass spectrometry identification were subjected to batch molecular docking using the ligant docking module (high throughput screening option) of Schrodinger software. On this basis, in order to further analyze the structure of the pentapeptide TPTLN and the binding effect of the receptor protein 6HUO, the pentapeptide TPTLN and GABA were also docked. A The receptor was docked using the ligant docking module (accurate docking option), and the specific results are as follows:
[0072] TPTLN and GABA A The receptor binding sites are: SER205, ASN60, TYR210, GLU138, THR207, LYS156, ASN103 and SER195 ( Figure 4 as shown).
[0073] GABA and GABA A Receptor binding, activation of GABA AReceptor, GABA A The acceptor is a Cl - Channel, GABA A Activation of the receptor leads to channel opening, Cl - The influx of TPTLN into nerve cells causes the hyperpolarization of the cell membrane, inhibits the excitation of the nerve cells, and thus plays a sedative and hypnotic role. A Receptor binding, directly activating GABA A receptors, increasing GABA A The sensitivity of the receptor to sodium pentobarbital, thus improving sleep. Based on the molecular docking technology analysis (ligant docking module for molecular docking, accuracy docking option), casein hydrolysate pentapeptide TPTLN and GABA A The binding energy of receptor binding is relatively high, and the binding energy and the number of hydrogen bonds are -8.722 and 8, respectively (this result is somewhat different from Table 1, because both of them are ligant docking modules selected, but the high-throughput screening option selected for batch docking in Table 1 has a low docking accuracy. After determining the peptide segment according to the screening results in Table 1, the accuracy docking option is reselected to obtain the binding energy and number of hydrogen bonds for accurate docking in this embodiment).
[0074] Example 3: Determination of sleep-promoting activity of TPTLN
[0075] 1. Experimental Materials
[0076] Experimental animals: ICR mice, male, 8 weeks old (20 ± 2 g), were purchased from Shanghai Slake Laboratory Animal Co., Ltd.
[0077] Normal saline;
[0078] Diazepam tablets (diazepam) (Tianjin Lisheng Pharmaceutical Co., Ltd.);
[0079] Pentobarbital sodium (Beijing Chemical Reagent Company);
[0080] GABA (Tianjin Century Weikang Biotechnology Co., Ltd.);
[0081] Pentapeptide TPTLN (commissioned to Shanghai Jier Biochemical Co., Ltd. for chemical synthesis).
[0082] 2. Experimental methods
[0083] ICR mice were allowed to eat and drink freely. All mice were allowed to adapt to the environment for one week (7 days) before the experiment. Then the experimental mice were divided into four groups for drug administration, with 10 mice in each group, namely the control group (Control), diazepam group, GABA group and pentapeptide TPTLN group. The details are as follows:
[0084] Blank control group: daily gavage with purified water;
[0085] Diazepam group: daily dose was 1 mg / kg bodyweight, twice a day;
[0086] GABA group: daily dose was 83.3 mg / kg bodyweight;
[0087] TPTLN group: daily dose was 5 mg / kg bodyweight.
[0088] The drug was administered continuously for 7 days, and each group had free access to food and water during the administration period. The experiment started 30 minutes after the last administration. At the beginning of the last administration of the mice, a stopwatch was used to count down for 30 minutes, and then 42 mg / kg of sodium pentobarbital was intraperitoneally injected into the four groups of mice. The injection time T1 was recorded at the same time. When the righting reflex of the mice disappeared, the righting reflex disappearance time T2 was recorded, which was the time when the mice began to fall asleep. When the righting reflex of the mice was restored, it was the time when the mice woke up T3. The sleep latency and sleep duration of the mice were calculated respectively. The shorter the sleep latency and the longer the sleep duration, the better the sleep-aiding effect of the peptide. The calculation formula is as follows:
[0089] Sleep latency = T2-T1; sleep time = T3-T2.
[0090] After the sleep recording was completed, the drug was administered at the above dose for 4 days. One hour after the last administration, the mice were euthanized, blood was collected from the eyeballs, plasma was collected, and centrifuged at 3000 rpm and 4°C for 15 min. The supernatant was collected and frozen in a -80°C refrigerator for subsequent analysis of changes in sleep-related neurotransmitters in serum, including (A) 5-HT, (B) GABA, (C) NE, (D) Glu, (E) 5-HIAA, (F) β-EP, (G) Cortisol, and (H) GABA / Glu. At the same time, the mouse brain was collected and placed at -80°C for subsequent analysis of changes in sleep-related neurotransmitters in mouse brain tissue, including (A) 5-HT, (B) GABA, (C) NE, (D) Glu, (E) β-EP, (F) Cortisol, and (G) GABA / Glu.
[0091] 3. Experimental results
[0092] (1) Sleep time results and analysis
[0093] Figure 5 A and 5B represent the sleep latency and sleep time of the pentapeptide TPTLN, respectively. The experiment used diazepam as a positive control. The results showed that diazepam can significantly shorten the sleep latency of mice and prolong the sleep time of mice. The experiment used GABA (83.3 mg / kg) as a comparison product, and the dosage of GABA was selected based on the maximum dose of GABA for humans of 500 mg / 60 kg body weight, which was converted to the corresponding dose of 83.3 mg / kg body weight for mice. The results showed that 5 mg / kg of pentapeptide TPTLN can significantly shorten the sleep latency of mice (p<0.05), and its effect is better than GABA; at the same time, GABA and TPTLN were shown to significantly prolong the sleep time of mice (p<0.01), and there was no significant difference between the two effects.
[0094] Table 2 Sleep latency and sleep time in different groups
[0095]
[0096] Note: “*”: compared with the control group, p<0.05; “**”: compared with the control group, p<0.01; “***”: compared with the control group, p<0.001.
[0097] (2) Analysis of the sleep-inducing, sedative, and stress-relieving effects of TPTLN
[0098] The occurrence of sleep is closely related to changes in neurotransmitters in the brain. For example, 5-HT in the brain can participate in the regulation of physiological functions such as appetite, pain, sleep and body temperature. The experiment analyzed the levels of sleep-related neurotransmitters in the serum and brain of mice ( Figure 6 & Figure 7 ) Further confirmed the sleep-inducing effect of TPTLN from the perspective of neurotransmitter changes.
[0099] 5-HT, also known as serotonin, is an important inhibitory neurotransmitter widely present in mammals. Its level is very high in the cerebral cortex and synapses, mainly distributed in the pineal gland and hypothalamus. The increase in 5-HT content can play a certain sedative and sleep-promoting role. The results showed that compared with the control group, diazepam and TPTLN can significantly increase the content of 5-HT in mouse serum ( Figure 6 A&7A), and the 5-HT content in the mouse brain was significantly higher after TPTLN treatment than that in the diazepam group ( Figure 7 A, p<0.0001 vs p<0.01), these results further confirmed the good sedative and sleep-inducing effects of TPTLN.
[0100] 5-Hydroxyindoleacetic acid (5-HIAA) is one of the metabolites of 5-HT and has no biological activity to promote sleep. Compared with the control group, diazepam, GABA and TPTLN can all reduce 5-HIAA in the serum of mice, but there is no significant difference ( Figure 6 E). These results suggest that TPTLN plays a role in promoting sleep by increasing the levels of 5-HT in the serum and brain of mice.
[0101] On the other hand, diazepam, GABA and TPTLN can significantly increase the GABA content in mouse serum ( Figure 6 B) However, compared with diazepam and GABA, only TPTLN can significantly upregulate the level of GABA in the mouse brain ( Figure 7 B, p<0.01). GABA is an important inhibitory neurotransmitter in the brain and activates GABA receptors to induce Cl - Channels open, increasing cell membrane resistance to Cl - The permeability of Cl - Flowing into nerve cells causes cell membrane hyperpolarization, inhibiting the excitement of neuronal cells, thus achieving a calming and hypnotic effect. This further verifies the good sleep-inducing effect of TPTLN.
[0102] Glu is the most abundant excitatory neurotransmitter in the brain. In the Glu system, Glu can activate Glu receptors on the postsynaptic membrane of Glu neurons, thereby triggering excitatory impulses. In the GABA system, Glu can enhance the GABA inhibitory tension in the entire pathway by activating presynaptic Glu receptors. Many substances that improve sleep work by improving the inhibitory / excitatory metabolic imbalance of GABA / Glu and regulating the GABA / Glu ratio. The experimental results showed that TPTLN can significantly increase the GABA / Glu ratio in both mouse serum and brain. This suggests that TPTLN can help with sleep by increasing the GABA / Glu ratio.
[0103] Norepinephrine (NE) is also a neurotransmitter that regulates the sleep-wake process. Its release peaks during wakefulness, and the reduction of NE helps promote sleep. The experimental results showed that TPTLN can significantly reduce the content of NE in the mouse brain ( Figure 7 C, p<0.05), and its effect was comparable to that of diazepam, suggesting that TPTLN can also play a good sleep-promoting role by inhibiting the synthesis of NE in the mouse brain.
[0104] β-Endorphin (β-EP) is an endogenous morphine-like substance belonging to the opioid peptide family. It has analgesic and pleasure-promoting effects. β-EP in serum can cross the blood-brain barrier and produce a sedative effect similar to opium in mice. The increase in β-EP content can play a certain role in promoting sleep. It is worth noting that compared with the control group, diazepam, GABA and TPTLN can significantly increase the level of β-EP in mouse serum ( Figure 6 F, p<0.05, p<0.05, p<0.0001, among which TPTLN had the strongest improvement effect ( Figure 6 F, p<0.001), and compared with the control group, only TPTLN could significantly increase the level of β-EP in the mouse brain ( Figure 7 E, p<0.05). These results suggest that TPTLN can play a good sedative and sleep-inducing effect by increasing the level of β-endorphin in the serum and brain of mice.
[0105] In summary, TPTLN mainly achieves a calming and sleep-inducing effect by upregulating the levels of sleep-related neurotransmitters such as 5-HT, GABA and β-EP in the serum and brain of mice, as well as the ratio of GABA / Glu, and downregulating the level of NE in the brain.
[0106] Although the present invention has been disclosed as above in terms of preferred embodiments, it is not intended to limit the present invention. Any person skilled in the art may make various changes, modifications, substitutions and variations in form and details to these embodiments without departing from the spirit and principles of the present invention. The scope of the present invention is defined by the claims and their equivalents.
Claims
1. Application of pentapeptide TPTLN, characterized in that: The invention is used in the preparation of medicines for preventing, improving or treating sleep disorders.
2. Application of pentapeptide TPTLN, characterized in that: The invention is used in preparing food for improving sleep disorders.
3. Application of pentapeptide TPTLN, characterized in that: The invention is used in preparing health care products for improving sleep disorders.
4. The use according to any one of claims 1 to 3, characterized in that: The sleep disorder is: reduced sleep time, difficulty falling asleep or poor sleep quality.
5. The use according to any one of claims 1 to 3, characterized in that: The sleep disorder is: insomnia.
6. The use according to claim 1, characterized in that The pentapeptide TPTLN is used alone in the preparation of the medicine, or is used in combination with other components having sleep-aiding activity.
7. The use according to claim 2, characterized in that The pentapeptide TPTLN is used alone in the preparation of the food, or is used in combination with other components having sleep-promoting activity.
8. The use according to claim 3, characterized in that The pentapeptide TPTLN is used alone in the preparation of the health care product, or is used in combination with other components having sleep-promoting activity.
9. The use according to claim 1, characterized in that The pentapeptide TPTLN is prepared in the form of oral liquid, capsule, microcapsule powder, tablet, granule or emulsion.
10. The use according to claim 2 or 3, characterized in that: The pentapeptide TPTLN is prepared in the form of beverage, oral liquid, capsule, microcapsule powder, tablet, granule or emulsion.
11. The use according to any one of claims 1 to 3, characterized in that: The pentapeptide TPTLN is separated and obtained from casein hydrolysate; the casein is bovine milk casein.
Citation Information
Patent Citations
Anxiolytic composition containing [alpha]s1-casein-derived peptides
CN102083453A
Novel protease and application thereof to casein phosphopeptide preparation
CN104774824A
Application of milk-derived active peptide CCL-3S in preparation of sleep promoting products
CN111632130A
Casein peptide with sleep improving effect and preparation method and application thereof
CN112409470A
Novel milk-derived active peptide CCL-4S capable of promoting sleep as well as preparation method and application thereof
CN113735957A
